Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies | ACS Medicinal Chemistry Letters

  1. Home
  2. Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies | ACS Medicinal Chemistry Letters
<< Back
April 28, 2023
by admin aurigene

Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies | ACS Medicinal Chemistry Letters